Cardiovascular Atlas
About
Menu

SELECT: semaglutide and cardiovascular outcomes in overweight or obesity

A large trial of adults aged 45 and over who already had heart or blood-vessel disease and were overweight or obese but did not have diabetes. Half took semaglutide 2.4 mg once a week and half took placebo. The semaglutide group had fewer combined events (heart attack, stroke or heart-related death). More people in the semaglutide group also stopped the medicine because of side effects.

Also called SELECT · Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

  • Study
  • In this atlas

Overview

Design
Multicenter, double-blind, randomized (1:1), placebo-controlled, event-driven superiority trial with parallel groups. The registry records phase 3 and quadruple masking.
Phase
Phase 3
Enrolled
  • 17,604 participants (enrolled count) (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity, retrieved )
Sponsor
Funder
Not recorded
Registry
  • NCT NCT03574597
Started
(actual) (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity, retrieved )
Primary completion
(actual) (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity, retrieved )
Completion
(actual) (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity, retrieved )
Results first posted
(actual) (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity, retrieved )
Countries
United States, Algeria, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Latvia, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, South Africa, Spain, Sweden, Taiwan, Thailand, Ukraine, United Kingdom, Türkiye (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity, retrieved )
Care setting
Not reported
Registry status
  • “COMPLETED” (U.S. National Library of Medicine (ClinicalTrials.gov), retrieved )

Technical summary

Double-blind, randomized, placebo-controlled, event-driven superiority trial sponsored by Novo Nordisk (NCT03574597). 17604 patients were enrolled, 8803 assigned to semaglutide 2.4 mg once weekly and 8801 to placebo. The primary outcome was the first of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke: hazard ratio 0.80 (95% CI 0.72 to 0.90) over a mean follow-up of 39.8 months. Adverse events that led to permanent discontinuation were 16.6% on semaglutide and 8.2% on placebo.

Arms

  • Semaglutide

    Intervention Semaglutide

    Once-weekly subcutaneous semaglutide at a dose of 2.4 mg, added to standard care.

  • Placebo

    Intervention None named

    Placebo, added to standard care.

Findings

No findings are published for this study.

Record details

Record id
cardio:select-trial
Content hash
35972f4e517a45d4af954b73efe6b0babc1c8eec7cea116fa5432e3d482cc221